OBJECTIVES: The role and clinical significance of fragile histidine triad (FHIT) gene in the pathogenesis of bladder urothelial carcinoma (UC) and the potential of Fhit protein as a prognostic biomarker for UC were investigated.
Introduction
Bladder cancer is the most common type of urothelial cancer (UC) 1 and the second most frequent malignancy of the genitourinary tract. 2 According to tumour, node, metastasis (TNM) classification, 3 bladder UC is classified into three types: superficial, confined to the bladder wall; and invasive. Most patients with bladder UC (75%) present with superficial tumours (pathological tumour in situ [pTis], pTa and pT1). 4 Regardless of treatment with surgery, chemotherapy, or immunotherapy, bladder UC may recur and/or metastasize. Though 1, 2 Fhit as a prognostic marker of bladder urothelial carcinoma mostly a superficial disease, it is difficult to predict its clinical behaviour. Recurrence of bladder UC is very high and, when it recurs, its pathological type is likely to be more progressive and differentiated. 5 Survival with advanced bladder UC is < 50%. 6 Highly complex oncogenic pathways are involved; therefore, new prognostic and predictive markers are needed in order to determine the best treatment for patients with bladder UC. The fragile histidine triad (FHIT) gene is a tumour suppressor gene that encompasses the genomic loci where fragile common sites map, and it overlaps the most active of the common fragile sites in the human genome, FRA3B (at HSA3p14.2). 7 The human FHIT gene is huge, spanning about 1.5 million bases at the FRA3B locus; however, it codes for a protein derived by the translation of 10 tiny exons, of which only exons 5 -9 contain the open reading frame, and its transcript is 1.1 kilobases and its protein just 147 amino acids. 8 Several studies have shown that the downregulation of Fhit protein might play an important role in the development of different cancers, and that Fhit protein is absent or reduced in most cancers in the early stages. 9, 10 Thus, measuring expression of the FHIT gene may prove to be a useful diagnostic and prognostic tool in evaluating the progression of cancer. Inactivation of the FHIT gene is related to the development of cancers of the breast, lung, stomach, pancreas, cervix and kidney. 11 -16 Since the FHIT gene is inactivated in so many cancers, it is important to examine its function in normal tissue and to analyse how the loss of its function contributes to the progression and development of cancers. The expression of FHIT in bladder UC and its clinical prognostic and predictive properties remain poorly understood.
The present study explored the clinical significance of the expression of the FHIT tumour suppressor gene in bladder UC and examined its role in the pathogenesis and prognosis of bladder UC.
Patients and methods

STUDY POPULATION AND SAMPLE COLLECTION
This retrospective study included consecutive patients with bladder UC who underwent radical bladder cancer surgery at the Second Hospital of Tianjin Medical University, Tianjin, China, between January 2003 and January 2005. All archival tissue samples were obtained from cystectomy specimens during surgery, and specimens from the bladder UC patients were diagnosed based on their histology following surgery in addition to their preoperative clinical diagnosis. Tumours were classified using the TNM 2002 and World Health Organization 1973 classifications 3,17 as follows: primary or recurrent; low grade (grade 1; G1) or high grade (grades 2 or 3; G2 or G3); papillary or nonpapillary growth pattern; depth of invasion ≤ 3 cm or > 3 cm; and nonmuscleinvasive (Tis, Ta, T1) or muscle-invasive (T2, T3, T4) stages. Tumour grade was classified as well-differentiated (low grade, G1) or moderately to poorly-differentiated (intermediate to high grade, G2 -G3). Patients with incidental tumours and other typical bladder tumours were excluded from the study. Eligible patients must have received no treatment prior to surgery. At the same time as samples were collected from UC patients, normal bladder epithelial tissues were collected from age-and gendermatched control patients with nonmalignant urinary diseases (including calculi of bladder cases and benign prostatic hyperplasia cases). These tissues were examined pathologically to exclude the possibility of incidental tumours and other typical bladder tumours. Some patients were CT Zhang, R Lu, YL Lin et al. Fhit as a prognostic marker of bladder urothelial carcinoma followed-up by telephone while others were followed-up as outpatients or as at-home visits.
This study was conducted in accordance with the international Declaration of Helsinki and was approved by the Ethical Committee of the Institutional Review Board of the Second Hospital of Tianjin Medical University, Tianjin, China. Written informed consent was obtained from each study participant.
IMMUNOHISTOCHEMISTRY
All specimens were fixed with 10% formalin and embedded in paraffin, and tissue sections (4 µm thick) were prepared and mounted on positively charged slides. For immunohistochemical staining of Fhit protein, routine deparaffinization of all sections was carried out, according to standard procedures, followed by rehydration through an ethanol series. The slides were immersed in citrate buffer (0.01 mol/l sodium citrate, pH 6.0) and heated in a microwave oven (600 W three times for 5 min) to enhance antigen retrieval. Endogenous peroxidase was blocked with 0.3% hydrogen peroxidase in methanol for 30 min. The sections were then incubated with an anti-Fhit rabbit polyclonal antibody (1 : 100 dilution; Zymed Laboratories, San Francisco, CA, USA) overnight at room temperature. The primary antibody was replaced by 0.01 M phosphate-buffered saline (PBS, pH 7.4) in the negative control. After incubation with the primary antibody, the sections were treated with biotinylated rabbit antibody (1 : 100 dilution; Zymed Laboratories) at 37°C for 30 min. The slides were washed three times with 0.01 M PBS after each antibody incubation step. The signal was developed using a streptavidin-biotinperoxidase Histostain ® -SP (streptavidinperoxidase) kit (Zymed Laboratories) with 3,3′-diaminobenzidine as a chromogen substrate. Finally, sections were washed in distilled water and weakly counterstained with Harris modified haematoxylin and eosin.
The samples were observed under a light microscope at × 200 and × 400 magnifications by two trained pathologists from Tianjin Second Hospital of Tianjin Medical University who were blinded to the patient survival data. Where differences occurred, consensus was achieved using a dual-headed microscope. Positive immunostaining for Fhit protein appeared as brown granules in the cell cytoplasm. Tissue sections were scored according to the percentage of tumour cells that were positive for Fhit protein, defined as: ≤ 10% (-); 11 -25% (+); 26 -50% (++); and ≥ 51% (+++). Patients were divided into two groups according to these definitions: positive FHIT expression was defined as patients having > 10% of cells positive for Fhit protein; and negative FHIT expression was defined as patients having ≤ 10% of cells positive for Fhit protein.
Negative FHIT expression was further defined as being completely negative, i.e. no immunohistochemical staining (0% of cells), or as heterogenous, i.e. small amounts of staining (≤ 10% of cells).
STATISTICAL ANALYSES
Statistical analysis was carried out using SPSS ® software package, version 16.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . Analysis of the association between FHIT expression and clinicopathological features was performed using either the χ 2 -test or a two-sided Fisher's exact test for normally and non-normally distributed data, respectively. The difference in overall survival between patients with positive or negative FHIT expression was calculated by the Kaplan-Meier method and compared by log rank analysis. Multivariate Cox proportional Fhit as a prognostic marker of bladder urothelial carcinoma hazard model analysis was used to assess the independent prognostic effect of FHIT expression after controlling for tumour stage and grade. A P-value < 0.05 was regarded as statistically significant.
Results
The study included 125 patients with bladder UC (83 males, 42 females; median age 66 years, range 32 -85 years). Mean follow-up was 53.5 months (range 3 -65 months). In the patient group there were 76 cases of nonmuscle-invasive cancers (Tis, Ta, T1) and 49 cases of muscle-invasive cancers (T2, T3, T4); 43 patients with G1, 47 with G2 and 35 with G3 tumours. Other clinicopathological features are shown in Fig. 1 .
Analysis of the relationship between FHIT expression, as measured by positive immunohistochemical staining for Fhit protein, and clinicopathological parameters showed significant associations between negative FHIT expression and advanced tumour stage (P = 0.0251), high grade tumours (P = 0.0315), large tumour size (P = 0.0406) and tumour recurrence (P = 0.0033), but no association with age, gender, tumour number or tumour shape (Table 1) .
Kaplan-Meier analysis showed that the survival of patients with FHIT positive expression in tumour tissues was significantly longer than for patients with FHIT negative expression (P = 0.012; Fig. 2 ).
Multivariate Cox proportional hazard model analysis was used to test for significant the dependent prognostic factor for survival amongst bladder UC patients. After controlling for tumour stage and grade, negative FHIT expression in tumour tissues had a statistically significant hazard ratio of 3.725 (95% CI 1.626 -10.352; P = 0.0121) for survival. Tumour stage and tumour grade were also found to be statistically significant dependent prognostic factors (P = 0.0109 and P = 0.0207, respectively, Table 2 ).
Discussion
Very little is known about the molecular aetiology of bladder UC, 18 but many oncogenes and tumour suppressor genes that may play a role in the pathogenesis of bladder UC have been identified and could be useful when determining patient 19 Cytogenetic and molecular genetic studies have shown many genetic alterations that affect tumour suppressor genes. 20 Mutations and/or deletions of the genes that encode for retinoblastoma, tumour protein 53, WAF1/CIP1, Fhit and cyclindependent kinase inhibitor 2a have been shown in bladder UC, 21 -23 but one of the most frequently deleted regions in the bladder UC genome has been shown to be located on the short arm of chromosome 3p14.2, which includes the FHIT gene. 24 Aberrations in the FHIT gene that result in the loss of Fhit protein have been described in numerous malignancies, including carcinomas of the lung, 25 uterine cervix 26 and breast. 11 There is also a report on the correlation between abnormalities in the FHIT gene and clinicopathological features in nonsmall cell lung cancer. 27 Deletions at the FHIT locus in 50% of bladder carcinoma-derived cell lines and reduced expression in 61% of primary transitional carcinomas of the urinary bladder have also been reported and, additionally, reintroduction of the FHIT gene into a FHIT-negative transitional carcinoma cell line using an adenoviral vector was shown to suppress tumorigenesis. 28 Thus, various studies have indicated that the FHIT gene plays a crucial role in the development and progression of bladder cancer.
The present study showed a significant association between reduced Fhit protein levels and bladder UC, suggesting that the loss of FHIT expression might be important in the pathogenesis and progression of bladder UC. This is consistent with another study that showed reduced or absent Fhit protein in other primary tumours, 29 and a study showing that reintroduction of the FHIT gene in FHIT-negative bladder carcinoma cell lines caused inhibition of cell growth and increased tumour cell death. 28 The present study also showed a significant association between reduced Fhit protein level and advanced tumour stage in bladder UC. A previous study showed that Fhit protein can induce apoptosis and alter cell-cycle kinetics in various cell lines. 30 It has been suggested that loss of Fhit protein is an important event in tumorigenesis and that FHIT plays an essential role in tumour progression. 31 The association between Fhit protein and clinicopathological features, including patient's age, gender, tumour number, tumour shape, tumour recurrence, tumour histological type and tumour size were also studied. Fhit protein levels were decreased in bladder UC development and this decrease was associated with tumour stage, grade, size and recurrence, but not with patients' age, gender, tumour number or tumour shape. Advanced stage, high grade and large tumour size are closely associated with the progression of bladder UC. 32 The degree of tumour differentiation and the high relapse rate are two important factors related with poor survival. 33 Downregulation of FHIT can promote cell proliferation. 34 The present study showed that FHIT expression in welldifferentiated tumours was reduced compared with moderately-or poorlydifferentiated tumours, suggesting an association between FHIT expression and tumour differentiation. Moreover, reduced FHIT expression occurred to a greater extent in larger tumours (> 3 cm), suggesting that decreased FHIT expression might facilitate tumour growth. Tumours > 3 cm have been shown to have an increased risk of developing into malignancy. 35 The expression of FHIT in patients who had recurrent tumours was significantly lower • Received for publication 8 November 2011 • Accepted subject to revision 6 December 2011
• Revised accepted 10 February 2012 Copyright © Field House Publishing LLP than those with primary tumours, suggesting that decreased expression of FHIT may contribute to an increased risk of recurrence of bladder UC.
The FHIT promoter is frequently methylated in bladder cancers (16%), leading to loss of Fhit protein, and methylation of the FHIT promoter region is associated with poor prognosis (high tumour grade, nonpapillary growth pattern, muscle invasion) and poor survival. 36 -38 Promoter methylation status was not evaluated in the present study, however, negative FHIT expression was seen in 52.8% of patients with bladder UC in the present study and was associated with a poor prognosis and shorter overall survival. This is consistent with studies in other cancers where aberrant expression of the FHIT gene has been reported to be associated with tumour progression and/or poor prognosis in carcinomas of the breast, 39 oesophagus, 40 pancreas, 41 and head and neck. 42 FHIT status was independently associated with poor survival in multivariate analysis, 38 and the expression profile of the FHIT gene may represent a potential new biomarker of risk prediction in bladder UC.
In conclusion, the present study suggests that FHIT expression might play an important role in tumour invasion, differentiation and growth in bladder UC, as well as providing information on prognosis and survival. Identifying changes in Fhit protein levels in bladder UC has the potential to provide important prognostic information. How the potential of the FHIT gene as a marker of patient prognosis and disease outcome may be translated into clinical practice remains to be elucidated. Studies with a larger number of patients are needed to confirm these findings.
Conflicts of interest
The authors had no conflicts of interest to declare in relation to this article.
